Introduction
============

Compulsive drug use and associated maladaptive behaviors are cardinal features of methamphetamine (METH) addiction, and have been strongly associated with the neurochemical consequences of repeated METH abuse ^[@ref-1]--\ [@ref-3]^. Among the various neurotransmitter systems affected by METH exposure is the glutamate system, where long-lasting drug-induced changes are suspected factors underlying craving and persistent vulnerability to relapse ^[@ref-4]^. Due to their dual roles in mediating glutamatergic synaptic plasticity and control of synaptic glutamate release, the metabotropic glutamate receptors (mGluRs) have emerged as therapeutic targets of interest in the study of drug addiction ^[@ref-5]^. Antagonizing the excitatory postsynaptic metabotropic glutamate receptor 5 (mGluR5) has been recently shown to attenuate the reinforcing effects of METH on a progressive ratio schedule, as well as attenuating drug-seeking behavior in rats previously trained to self-administer METH ^[@ref-6]^. Selective stimulation of mGluR5 has been found to improve the rate of extinction learning in rats previously conditioned to the reinforcing effects of cocaine. This study investigated the role of mGluR5 in the behavioral changes induced by repeated exposure to METH, using positive and negative allosteric modulators of mGluR5 function in separate experiments.

The consequences of chronic METH abuse are often studied in the rat model of behavioral sensitization, where chronic METH injections reliably induce an elevated locomotor response to a subsequent METH challenge, relative to rats with no prior history of METH exposure ^[@ref-8]--\ [@ref-11]^. Through their interactions with the dopaminergic projections of the medial forebrain, mGluRs have been found to have roles in both the development and expression of psychostimulant sensitization ^[@ref-12]^. mGluR5 has been associated with the locomotor response and reinforcement attributes of psychostimulants since mice lacking this receptor were found not to respond to or self-administer cocaine as wild-type mice ^[@ref-13]^. While antagonism of group I mGluRs, which includes mGluR5, in subsequent experiments has generally failed to convincingly affect locomotor sensitization to cocaine ^[@ref-14]^, the effects of positive allosteric modulation on psychostimulant sensitization have so far remained untested. We evaluated the effect of the mGluR5 positive allosteric modulator (PAM) 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) and the mGluR5 negative allosteric modulator (NAM) fenobam on the expression of behavioral sensitization to METH. We utilized doses of CDPPB that have been shown to improve extinction learning after METH \[30 mg/kg ^[@ref-15]^\], and cocaine \[60 mg/kg ^[@ref-7]^\], self-administration training, and doses of fenobam (10--30 mg/kg) that have effectively reduced drug-seeking in METH-trained rats in our laboratory ^[@ref-16]^.

Methods and materials
=====================

Subjects
--------

Eighty-eight male Sprague-Dawley rats (Harlan Laboratories, Livermore, CA), weighing 250--275 g, were pair-housed on arrival in a humidity-controlled colony room and maintained in a reversed light/dark cycle with free access to food and water throughout the experiment. All experimentation was conducted during the dark phase of the light/dark cycle. All procedures were conducted with the approval of the Institutional Care and Use Committee at Arizona State University and in accordance with the principles of the Guide for the Care and Use of Laboratory Animals (National Research Council) ^[@ref-17]^.

Drugs
-----

3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB, custom synthesized by Chemir Analytical Services, Maryland Heights, MO) was suspended in 10% *v/v* Tween 80 via sonication to form a 60 mg/ml concentration for intraperitoneal (i.p.) administration. Fenobam (1-(3-chlorophenyl)-3-3-methyl-5-oxo-4H-imidazol-2-yl) urea (custom synthesized by Chemir Analytical Services) was suspended in 0.3% *v/v* Tween 80 vehicle to form a 30 mg/ml concentration for i.p. administration. (+)Methamphetamine hydrochloride (Sigma Aldrich, St Louis, MO) was dissolved in sterile saline for i.p. administration.

Locomotor testing procedures
----------------------------

Locomotor activity was assessed in a Rotorat System apparatus (Med Associates, Mt. St Albans, VT) that measured rotational ambulation, quantified as quarter turns in both directions, within a bowl-shaped arena ( [Figure 1A](#f1){ref-type="fig"}). The rats ( *N*=43 in the CDPPB experiment, *N*=45 in the fenobam experiment) were divided into groups where half of the rats received five injections of 1 mg/kg METH dissolved in saline (1 ml/kg, i.p.), separated by 48 hours, and the other half received injections of saline of matching volume ( [Figure 1B](#f1){ref-type="fig"}). Each injection was immediately followed by a 90 min locomotor test session. After a 6-day waiting period in the colony room, all rats were given a saline injection (1 ml/kg, i.p.) and subjected to a locomotor test session. The next day, rats were injected with 0 ( *N*=7), 30 ( *N*=8) or 60 mg/kg ( *N*=6--7) CDPPB in one experiment; or 0 ( *N*=8), 10 ( *N*=8) or 30 mg/kg ( *N*=6--7) fenobam in the other experiment, and 30 min later given a challenge dose of 0.5 mg/kg METH and subjected to a 90 min locomotor test session.

![Apparatus and experimental protocol.\
The locomotor apparatus ( **A**) consists of a rotating actuator anchored to a U-shaped bracket over a steel bowl-shaped arena (Med Associates; 18 in top diameter, 6 in bottom diameter, 6 in depth) containing a layer of Sani-chip bedding. The rat is attached to the actuator via 45 cm spring leash terminated with an alligator clip, which is hooked onto a cable tie around the neck for the duration of the test session. The apparatus registers rotational movements as the rat causes the actuator to pivot, accumulated by computer as quarter turns. The experimental procedure ( **B**) consisted of three days of acclimation sessions in the locomotor arenas, followed by five injections of METH (1.0 mg/kg, i.p.) or saline separated by 48 hr (Days 1, 3, 5, 7 and 9). After each injection, rats were placed into the locomotor arenas for 90 min and their rotational data were recorded as quarter turns. Rats underwent locomotor testing following a saline injection on Day 15, and these data were balanced between groups assigned to mGluR5 treatment or vehicle treatment. On Day 16, the rats were given an injection of the mGluR5 ligand (CDPPB or fenobam) or vehicle, and tested 30 min later following a probe injection of METH (0.5 mg/kg, i.p.).](f1000research-2-864-g0000){#f1}

Additional experiments were conducted to examine the effects of mGluR5 modulation on baseline locomotion. Rats were acclimated to the apparatus in 90 min sessions for two consecutive days, and on the next day given a 90 min locomotor test session 30 min after treatment with 0, 30 or 60 mg/kg CDPPB in one experiment ( *N*=5); or 0, 10 or 30 mg/kg fenobam in another experiment ( *N*=5).

Data analysis
-------------

Data analysis procedures were performed using Prism 5 (GraphPad, La Jolla, CA). For the sensitization experiments, quarter turn data (in either direction, totaled over 90 min) taken during the five chronic treatment sessions were analyzed using 2-way ANOVA with *METH history* (naïve, METH-treated) as a between-subjects factor and *day* (1, 3, 5, 7 or 9) as a within-subjects factor. Locomotor behavior exhibited during the challenge sessions were quantified as quarter turns and analyzed using 2-way ANOVA with *METH history* and *treatment* (0, 30 or 60 mg/kg for the CDPPB experiment, and 0, 15 or 30 mg/kg for the fenobam experiment) as between-subjects factors. Significant interaction effects were followed by pairwise comparisons (Fisher's LSD tests).

In the baseline locomotion experiments, quarter turn data were analyzed using one-way ANOVA with CDPPB or fenobam treatment as the main factor.

Results
=======

Elevated locomotion as a consequence of repeated METH treatment
---------------------------------------------------------------

In the CDPPB experiment, rats treated with repeated METH injections exhibited progressively increasing amounts of quarter turns, as confirmed by a significant main effect of *METH history* ( *F* ~1,164~ = 51.8, *p* \< 0.0001) and a *day* × *METH history* interaction ( *F* ~4,164~ = 3.4, *p* \< 0.05). In these rats, locomotion was significantly elevated from Day 1 levels (2110 ± 284) on Day 5 (3117 ± 401, *p* \< 0.05, Fisher's LSD test) and Day 7 (3432 ± 433, *p* \< 0.01), but not Day 9 ( [Figure 2A](#f2){ref-type="fig"} and [Table S1](#TS1){ref-type="table"}-- [Table S2](#TS2){ref-type="table"}). Similarly, in the fenobam experiment, repeated injections of METH but not saline resulted in elevated quarter turns, as confirmed by significant main effects of *day* ( *F* ~4,172~ = 4.1, *p* \< 0.005) and *METH history* ( *F* ~1,172~ = 60.9, *p* \< 0.0001) and a *day* × *METH history* interaction ( *F* ~4,172~ = 6.0, *p* \< 0.0005). In these rats, locomotion was significantly elevated from Day 1 levels (2175 ± 320) on Day 5 (3136 ± 297, *p* \< 0.05, Fisher's LSD test), Day 7 (3548 ± 388, *p* \< 0.01) and Day 9 (3469 ± 438, *p* \< 0.05, [Figure 2B](#f2){ref-type="fig"} and [Table S3](#TS3){ref-type="table"}-- [Table S4](#TS4){ref-type="table"}).

![Effects of mGluR5 treatment by CDPPB (top row) or fenobam (bottom row) on locomotion and methamphetamine (METH) behavioral sensitization.\
In locomotor sessions prior to mGluR5-targeted treatment ( **A-B**), rats were chronically given 1 mg/kg METH (filled circles) or saline (open circles). In both the CDPPB ( **A**) and fenobam ( **B**) experiments, the reported quarter turns progressively increased above first-day levels in the METH-exposed groups. \* *P* \< 0.05 different from Day 1 levels. In the subsequent test using 0.5 mg/kg METH in all groups ( **C**), rats with a history of chronic METH exposure exhibited elevated locomotor behavior, but CDPPB pretreatment had no effect. In the fenobam experiment ( **D**), rats with a history of chronic METH exposure also exhibited elevated locomotor activity, and this behavioral sensitization was not affected by 10 mg/kg fenobam pretreatment. After 30 mg/kg fenobam treatment, the METH-sensitized locomotor response was reduced from the vehicle level. \* *P* \< 0.05 difference between METH history groups, regardless of mGluR5 ligand treatment. + *P* \< 0.05 different from vehicle treated group with matching history of METH exposure. *PAM* stands for positive allosteric modulation, and *NAM* stands for negative allosteric modulation.](f1000research-2-864-g0001){#f2}

Effect of mGluR5 modulation on locomotor sensitization to METH
--------------------------------------------------------------

In the CDPPB experiment, rats with a history of repeated METH treatments exhibited a greater number of quarter turns following a probe injection of 0.5 mg/kg METH, evidence of locomotor sensitization ( [Figure 2C](#f2){ref-type="fig"} and [Table S5](#TS5){ref-type="table"}-- [Table S6](#TS6){ref-type="table"}). This elevated response to METH was not attenuated by CDPPB pretreatment, as shown by the existence of a main effect of *METH history* ( *F* ~1,37~ = 10.7, *p* \< 0.005) but no other main effects or interactions.

In the fenobam experiment, rats with a history of repeated METH treatments also exhibited elevated quarter turns following the 0.5 mg/kg METH probe ( [Figure 2D](#f2){ref-type="fig"} and [Table S7](#TS7){ref-type="table"}-- [Table S8](#TS8){ref-type="table"}). Pretreatment with fenobam attenuated the locomotor response to METH, regardless of METH exposure history, as revealed by the presence of main effects of *METH history* ( *F* ~1,39~ = 20.1, *p* \< 0.001) and *treatment* ( *F* ~2,39~ = 6.7, *p* \< 0.005), but no *METH history × treatment* interaction. However, pretreatment with the large dose of fenobam (30 mg/kg) resulted in significantly reduced METH-induced locomotion in rats with a history of chronic 1 mg/kg METH injections (0 mg/kg fenobam: 1192 ± 105 quarter turns vs. 30 mg/kg fenobam: 597 ± 150 quarter turns, *p* \< 0.01, two-sample *t*-test), and produced a trend toward a significant reduction in rats with a history of saline injections (0 mg/kg fenobam: 622 ± 493 quarter turns vs. 30 mg/kg fenobam: 405 ± 106 quarter turns, P = 0.08).

Effect of mGluR5 modulation on baseline locomotion
--------------------------------------------------

All of the tested doses of CDPPB and fenobam had negligible effects on baseline locomotion, measured 30 min after time of injection. Both the 60 mg/kg dose of CDPPB (300 ± 92 quarter turns, vs. 345 ± 43 for the vehicle) and the 30 mg/kg dose of fenobam (389 ± 59 quarter turns, vs. 407 ± 74 for the vehicle) produced slightly attenuated locomotor responses, but no significant effects were revealed by ANOVA in either experiment ( [Figure 3](#f3){ref-type="fig"} and [Table S9](#TS9){ref-type="table"}-- [Table S10](#TS10){ref-type="table"}).

![Effects of mGluR5 treatment on baseline locomotion in previously drug-naïve rats.\
CDPPB ( **A**) or fenobam ( **B**) was injected 30 min prior to locomotor testing. No significant effects were reported from the quarter turns collected over 90 min sessions.](f1000research-2-864-g0002){#f3}

Discussion
==========

As expected, rats repeatedly injected with 1 mg/kg METH exhibited greater locomotor activity than the saline-treated rats, and demonstrated more activity during the latter sessions than the initial session. Treatment with CDPPB did not significantly alter METH-induced rotational locomotion, and treatment with fenobam only significantly reduced rotational locomotion at its highest dose (30 mg/kg). Neither CDPPB nor fenobam significantly attenuated the baseline locomotor activity of drug-naïve animals, although the small effect found for 30 mg/kg fenobam in that experiment ( [Figure 3B](#f3){ref-type="fig"}) could explain the moderate reduction of quarter turns exhibited by METH-challenged rats ( [Figure 2D](#f2){ref-type="fig"}) as a non-specific phenomenon. Thus, locomotor effects of mGluR5 modulation were largely absent at the dose ranges that have been shown in earlier studies to reduce operant behavior motivated by METH or cocaine training ^[@ref-7],\ [@ref-15],\ [@ref-16],\ [@ref-18],\ [@ref-19]^.

These largely negative findings indicate that the maintenance of behavioral sensitization is likely mediated by neurobiological substrates other than mGluR5. These data are also in agreement with previous observations that mGluR5 function does not appear critical for the expression of locomotor sensitization to cocaine ^[@ref-14],\ [@ref-20]^, and extends them to include METH sensitization. Furthermore, the contribution of mGluR5 to initial locomotor responses to injected psychostimulants ^[@ref-13]^ appears to be replaced by other neurochemical substrates with chronic drug exposure.

While mGluR5 is an important therapeutic target in researching treatments for addiction to psychostimulants as well as other abused substances, there is building evidence that the role of this receptor in drug-related behaviors changes with increasing exposure. A recent study of rats chronically exposed to METH sufficient to induce measurable conditioned place preference found a reduction of surface expression of mGluR5 in the medial prefrontal cortex ^[@ref-21]^, an area known to contribute to the expression of behavioral sensitization ^[@ref-4]^. The current findings using the behavioral sensitization model therefore suggest that the changes in the degree to which mGluR5 mediates drug-stimulated and drug-conditioned behavior previously shown to occur with chronic cocaine exposure might also take place in rats with a history of chronic METH exposure. The possibility of the changing roles among the various mGluR subfamilies as a result of drug exposure merits further studies utilizing animal models of METH-induced activity and motivated behavior.

The authors wish to acknowledge Angel Villa, Kaveish Sewalia, Elisabeth Moore, Casey Halstengard, Piroska Barabas and Lauren Hood of Arizona State University for providing valuable technical assistance.

Supplementary tables
====================

###### CDPPB experiment -- locomotor response (total quarter turns over 90 min) after chronic METH treatments.

In locomotor sessions prior to mGluR5-targeted treatment, rats were chronically given 1 mg/kg METH i.p. In this experiment, the reported quarter turns progressively increased above first-day levels.

  Rat       Day of treatment (1 mg/kg METH)                        
  --------- --------------------------------- ------ ------ ------ ------
  **203**   2419                              2269   3200   4701   1648
  **205**   3840                              3197   2640   6428   1867
  **213**   2436                              1520   3379   1243   2273
  **234**   585                               990    913    950    577
  **238**   2119                              1539   1046   2845   1151
  **242**   1487                              1825   1215   1412   1606
  **244**   987                               1063   3221   3230   1475
  **201**   2907                              2145   3695   5875   4264
  **207**   1454                              1568   3963   3442   2566
  **211**   3581                              2512   3086   3152   5037
  **215**   1534                              1727   3699   1804   1655
  **232**   726                               1229   1567   1737   1492
  **236**   3436                              7602   6724   7647   7239
  **246**   2275                              2439   6851   5386   4959
  **248**   818                               2449   1101   1434   2336
  **253**   1016                              1599   1306   1097   3678
  **254**   415                               3854   1492   4504   2005
  **255**   4608                              5091   3499   3836   3150
  **256**   1672                              1794   5353   4008   9378
  **257**   1160                              2158   5724   1625   1425
  **258**   4639                              6600   1770   5712   1024

###### CDPPB experiment -- locomotor response (total quarter turns over 90 min) after saline treatments.

In locomotor sessions prior to mGluR5-targeted treatment, rats were chronically given 1 ml/kg saline i.p. The reported quarter turns did not significantly change from first-day levels.

  Rat       Day of treatment (saline)                        
  --------- --------------------------- ------ ------ ------ ------
  **202**   397                         248    181    301    359
  **206**   2964                        247    1240   969    1621
  **214**   342                         408    1202   539    557
  **235**   644                         1205   750    858    653
  **237**   668                         919    863    983    675
  **241**   295                         516    890    634    646
  **212**   423                         607    322    442    289
  **243**   420                         557    331    449    683
  **204**   448                         321    435    367    288
  **208**   923                         940    730    855    1098
  **216**   2078                        1246   1651   960    1563
  **231**   653                         895    711    604    494
  **233**   1265                        640    803    917    612
  **245**   1488                        1151   817    820    1138
  **247**   477                         549    723    1160   885
  **251**   74                          178    381    214    424
  **252**   67                          26     77     124    128
  **271**   316                         797    454    391    298
  **272**   202                         202    190    226    136
  **275**   1288                        495    642    1063   495
  **263**   959                         681    941    576    681
  **264**   922                         490    421    347    445

###### Fenobam experiment -- locomotor response (total quarter turns over 90 min) after chronic METH treatments.

In locomotor sessions prior to mGluR5-targeted treatment, rats were chronically given 1 mg/kg METH i.p. In this experiment, the reported quarter turns progressively increased above first-day levels.

  Rat       Day of treatment (1 mg/kg METH)                        
  --------- --------------------------------- ------ ------ ------ ------
  **362**   315                               1314   1818   1068   966
  **364**   1691                              1869   4040   3447   2381
  **366**   3813                              2074   3556   6491   7163
  **368**   1261                              2087   926    1961   2489
  **377**   1888                              3952   4491   3738   3905
  **383**   1547                              1065   3203   3511   2747
  **385**   1989                              1586   2476   3679   2865
  **387**   1214                              1960   536    1807   963
  **352**   1983                              1325   1693   1853   1865
  **354**   2966                              2963   4444   4726   5932
  **356**   7984                              5835   6043   6727   7125
  **358**   1798                              4432   3827   7331   6979
  **371**   2167                              2344   2538   2110   3273
  **373**   2342                              3220   1545   2069   2442
  **375**   1796                              3876   2117   3638   2653
  **381**   1863                              2059   3483   3319   3158
  **313**   676                               3157   2552   2467   5972
  **314**   1868                              5270   5345   2352   5141
  **315**   3195                              2660   3308   6766   951
  **316**   1600                              6267   3301   3516   3549
  **317**   1741                              3105   3223   1767   717
  **318**   2154                              2530   4528   3704   3091

###### Fenobam experiment -- locomotor response (total quarter turns over 90 min) after saline treatments.

In locomotor sessions prior to mGluR5-targeted treatment, rats were chronically given 1 ml/kg saline i.p. The reported quarter turns did not significantly change from first-day levels.

  Rat       Day of treatment (1 mg/kg saline)                        
  --------- ----------------------------------- ------ ------ ------ ------
  **351**   979                                 1042   670    763    727
  **357**   2092                                2047   1343   1656   1664
  **361**   418                                 369    348    387    433
  **367**   1309                                1444   1751   1440   1480
  **372**   345                                 244    486    430    359
  **374**   1120                                1177   847    1412   1195
  **384**   1307                                613    878    598    730
  **386**   1216                                1368   939    1246   633
  **353**   852                                 701    466    528    636
  **355**   452                                 452    320    1445   1010
  **363**   735                                 1092   1185   1084   733
  **365**   1308                                2251   2095   1649   1018
  **376**   1406                                748    1147   1024   1078
  **378**   1146                                762    816    948    599
  **382**   540                                 191    393    438    567
  **388**   1338                                1233   970    1146   678
  **311**   225                                 378    219    390    362
  **312**   192                                 255    152    297    161
  **323**   959                                 1028   941    576    681
  **324**   922                                 490    421    347    445
  **331**   316                                 797    454    391    298
  **332**   202                                 202    190    226    136
  **335**   1288                                1623   642    1063   495

###### CDPPB (0, 30, 60 mg/kg) effects on METH locomotor response (total quarter turns over 90 min) -- rats with histories of saline injections.

In the Day 16 tests using 0.5 mg/kg METH in all groups, rats with a history of chronic saline injections exhibited elevated locomotor behavior, but CDPPB pretreatment had no effect.

  Rat       CDPPB   Quarter turns
  --------- ------- ---------------
  **202**   0       910
  **206**   0       215
  **214**   0       363
  **235**   0       952
  **237**   0       1001
  **241**   0       871
  **212**   0       135
  **243**   30      1495
  **204**   30      885
  **208**   30      129
  **216**   30      692
  **231**   30      281
  **233**   30      744
  **245**   30      683
  **247**   30      539
  **251**   60      1117
  **252**   60      358
  **271**   60      668
  **272**   60      127
  **275**   60      1113
  **263**   60      681
  **264**   60      622

###### CDPPB effects on METH locomotor response (total quarter turns over 90 min) -- rats with histories of METH injections.

In the Day 16 tests using 0.5 mg/kg METH in all groups, rats with a history of chronic METH exposure exhibited elevated locomotor behavior, but CDPPB pretreatment had no effect.

  Rat       CDPPB   Quarter turns
  --------- ------- ---------------
  **203**   0       1425
  **205**   0       1767
  **213**   0       1112
  **234**   0       933
  **238**   0       1100
  **242**   0       653
  **244**   0       1475
  **201**   30      542
  **207**   30      1674
  **211**   30      1325
  **215**   30      1701
  **232**   30      904
  **236**   30      1858
  **246**   30      3808
  **248**   30      210
  **253**   60      345
  **254**   60      397
  **255**   60      1675
  **256**   60      1414
  **257**   60      1252
  **258**   60      1662

###### Fenobam (0, 10, 30 mg/kg) effects on METH locomotor response (total quarter turns over 90 min) -- history of saline injections.

In the Day 16 tests using 0.5 mg/kg METH in all groups, rats with a history of chronic saline injections exhibited elevated locomotor behavior, but fenobam pretreatment had no effect.

  Rat       Fenobam   Quarter turns
  --------- --------- ---------------
  **351**   0         257
  **357**   0         770
  **361**   0         661
  **367**   0         909
  **372**   0         449
  **374**   0         587
  **384**   0         693
  **386**   0         656
  **353**   10        748
  **355**   10        181
  **363**   10        394
  **365**   10        725
  **376**   10        298
  **378**   10        910
  **382**   10        480
  **388**   10        207
  **311**   30        315
  **312**   30        101
  **323**   30        274
  **324**   30        219
  **331**   30        955
  **332**   30        465
  **335**   30        508

###### Fenobam (0, 10, 30 mg/kg) effects on METH locomotor response -- history of METH injections.

In the Day 16 tests using 0.5 mg/kg METH in all groups, rats with a history of chronic METH exposure exhibited elevated locomotor behavior, and 30 mg/kg but not 10 mg/kg fenobam resulted in reduced quarter turns relative to vehicle-pretreated animals.

  Rat       Fenobam   Quarter turns
  --------- --------- ---------------
  **362**   0         1551
  **364**   0         1190
  **366**   0         1111
  **368**   0         611
  **377**   0         1509
  **383**   0         1354
  **385**   0         1050
  **387**   0         1162
  **352**   10        929
  **354**   10        1263
  **356**   10        1084
  **358**   10        1391
  **371**   10        861
  **373**   10        614
  **375**   10        281
  **381**   10        1009
  **313**   30        275
  **314**   30        927
  **315**   30        419
  **316**   30        619
  **317**   30        218
  **318**   30        1129

###### Locomotor response (total quarter turns over 90 min) to CDPPB (0, 30, 60 mg/kg).

  Rat       CDPPB   Quarter turns
  --------- ------- ---------------
  **101**   0       304
  **104**   0       171
  **107**   0       490
  **110**   0       353
  **113**   0       407
  **102**   30      353
  **105**   30      401
  **108**   30      198
  **111**   30      384
  **114**   30      307
  **103**   60      650
  **106**   60      120
  **109**   60      245
  **112**   60      199
  **115**   60      285

###### Locomotor response (total quarter turns over 90 min) to Fenobam (0, 10, 30 mg/kg).

  Rat       Fenobam   Quarter turns
  --------- --------- ---------------
  **403**   0         365
  **406**   0         577
  **409**   0         584
  **412**   0         226
  **415**   0         286
  **401**   10        317
  **404**   10        468
  **407**   10        339
  **410**   10        274
  **413**   10        817
  **402**   30        478
  **405**   30        465
  **408**   30        274
  **411**   30        219
  **414**   30        508
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Specifically, while the authors methodologically included a saline challenge when assessing the expression of sensitization, they failed to report these results. Without this it is not possible to determine if indeed the increase in locomotor activity observed in the METH pre-treatment group is due to expression of conditioned hyperactivity or locomotor sensitization. I suspect it may be the former due to the apparently reduced locomotor activity (approx 1200) observed during this challenge session even when compared to acute METH (approx 2000). Usually expression of locomotor sensitization is much greater than the final conditioning session. It is therefore unreasonable for the authors to conclude that PAM or NAM of mGluR5 has no effect on expression of sensitization as it is not even clear if the animals are expressing sensitized behaviour. Inclusion of the saline challenge data will clarify this point. 

Have the authors considered using a longer 'waiting' period between development and testing expression? A recent study by [Timmer and Steketee, 2012](http://www.ncbi.nlm.nih.gov/pubmed/22147256) found that intra-prefrontal cortex injections of the mGluR5 PAM MTEP reduced the expression of locomotor sensitization to cocaine following 21 days but not 7 days. The authors should include this in the discussion of their results.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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Although this is a report of primarily negative findings it is not without value and should be published. The premise of the research is reasonable, the methods appropriate and the conclusions appropriate and not overreaching.  Essentially, the workers have demonstrated through behavioural studies in rats that allosteric modulation -- either positive or negative -- of the metabotropic glutamate receptor 5 does not modify methamphetamine-induced behavioural sensitization. This adds to our knowledge of the effects of methamphetamine in its abuse.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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